Erratum: Expression of Concern (Biological Psychiatry (2010) 67(6) (522–530), (S0006322309011792), (10.1016/j.biopsych.2009.09.031));S 24795 Limits β-Amyloid-α7 Nicotinic Receptor Interaction and Reduces Alzheimer's Disease-Like Pathologies

Biological Psychiatry

Volumn 67, Issue 6, 2010, Pages 522-530

  Wang, Hoau Yan ^b   Bakshi, Kalindi ^b   Shen, Changpeng ^b   Frankfurt, Maya ^b   Trocmé Thibierge, Caryn ^a   Morain, Philippe ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; nicotinic receptor agonist; NMDA receptor; synaptic dysfunction; 7 nicotinic acetylcholine receptor; amyloid

Indexed keywords

2 [2 (4 BROMOPHENYL) 2 OXOETHYL] 1 METHYL PYRIDINIUM; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; BUNGAROTOXIN RECEPTOR; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINIC AGENT; S 24795; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SLICE; BRAIN SYNAPTOSOME; BRAIN TISSUE; CALCIUM TRANSPORT; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RAT;

EID: 76849083911     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2024.06.006     Document Type: Erratum

References (48)

1. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann N Y Acad Sci 924 (2000) 17-25
2. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 (2000) 1571-1577
3. 1-42 binds to α7 nicotinic acetylcholine receptor with high affinity: Implications for Alzheimer's disease pathology. J Biol Chem 275 (2000) 5626-5632
4. 1-42 binds selectively and with pico-molar affinity to α7 nicotinic acetylcholine receptors. J Neurochem 75 (2000) 1155-1161
5. Nagele R.G., D'Andrea M.R., Anderson W.J., and Wang H.Y. Intracellular accumulation of beta-amyloid (1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 110 (2002) 199-211
6. Wang H.Y., Li W., Benedetti N., and Lee D.H.S. α7 nicotinic acetylcholine receptors α7 nicotinic acetylcholine receptors mediate β-amyloid peptides-induced tau protein phosphorylation. J Biol Chem 278 (2003) 31547-31553
7. 1-42 peptide directly modulates nicotinic receptors in the rat hippocampal slice. J Neurosci 21 (2001) RC120-RC125
8. Liu Q.S., Kawai H., and Berg D.K. Beta-amyloid peptide blocks the response of alpha7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 48 (2001) 4734-4739
9. Lee D.H.S., and Wang H.Y. Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid1-40 and beta-amyloid1-42. J Neurobiol 55 (2003) 25-30
10. Cincotta S.L., Yorek M.S., Moschak T.M., Lewis S.R., and Rodefer J.S. Selective nicotinic acetylcholine receptor agonists: Potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs 9 (2008) 47-59
11. Lopez-Hernandez G., Placzek A.N., Thinschimdt J.S., Lestage P., Trocme-Thibierge C., Morain P., et al. Partial agonist and neuromodulatory activity of S 24795 for alpha7 nAChR responses of hippocampal interneurons. Neuropharmacology 53 (2007) 134-144
12. Lagostena L., Trocme-Thibierge C., Morain P., and Cherubini E. The partial α7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 54 (2008) 676-685
13. Beracochea D., Boucard A., Trocme-Thibierge C., and Morain P. Improvement of contextual memory by S 24795 in aged mice: Comparison with memantine. Psychopharmacology 196 (2008) 555-564
14. Marighetto A., Valerio S., Desmedt A., Philippin J.P., Trocmé-Thibierge C., and Morain P. Comparative effects of the α7 nicotinic partial agonist, S 24795 and cholinesterase inhibitor donepezil against aging-related deficits in declarative and working memory in mice. Psychopharmacology 197 (2008) 499-508
15. Stoppini I., Bushs P.A., and Mulker D. A simple method for organotypic cultures of nervous tissue. J Neurosci Methods 37 (1991) 173-182
16. Adamchik Y., Frantseva M.V., Weisspapir M., Carlen P.L., and Perez-Velazquez J.L. Methods to induce primary and secondary traumatic damage in organotypic hippocampal slices cultures. Brain Res Protoc 5 (2000) 153-158
17. Flood J.F., Morley J.E., and Roberts E. Amnestic effects in mice of four synthetic peptides homologous to amyloid beta protein from patients with Alzheimer's disease. Proc Natl Acad Sci U S A 88 (1991) 3363-3366
18. Yamada Y., and Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol Ther 88 (2000) 93-113
19. D'Andrea M.R., Nagele R.G., Wang H.Y., Peterson P.A., and Lee D.H.S. Evidence that neurons accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology 38 (2001) 120-134
20. Battaglia F., Wang H.Y., Ghilardi M.F., Gashi E., Quartarone A., Friedman E., et al. Cortical plasticity in Alzheimer's disease in humans and rodents. Biol Psychiatry 62 (2007) 1405-1412
21. LaFerla F.M., Tinkle B.T., Bieberich C.J., Haudenschild C.C., and Jay G. The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet 1 (1995) 21-30
22. LaFerla F.M., Troncoso J.C., Strickland D.K., Kawas C.H., and Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Abeta stabilization. J Clin Invest 100 (1997) 310-320
23. Gouras G.K., Tsai J., Naslund J., Vicent B., Edgar M., Checler F., et al. Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156 (2000) 15-20
24. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple- transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
25. Takahashi R.H., Milner T.A., Li F., Nam E.E., Edgar M.A., Yamaguchi H., et al. Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161 (2002) 1869-1879
26. Perry G., Cras P., Siedlak S.L., Tabaton M., and Kawai M. Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 140 (1992) 283-290
27. Zhang Y., McLaughlin R., Goodyer C., and LeBlanc A. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 156 (2000) 519-529
28. Tseng B.P., Kitazawa M., and LaFerla F.M. Amyloid beta-peptide: The inside story. Curr Alzheimer Res 1 (2004) 231-239
29. Dineley K.T., Westereman M., Bui D., Bell K., Ashe K.H., and Sweatt J.D. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 21 (2001) 4125-4133
30. Liu Q., Huang Y., Xue F., Simard A., DeChon J., Li G., et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29 (2009) 918-929
31. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8 (2005) 1051-1058
32. Mansvelder H.D., and McGehee D.S. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron 27 (2000) 349-357
33. Fujii S., Jia Y., Yang A., and Sumikawa K. Nicotine reverses GABAergic inhibition of long-term potentiation induction in the hippocampal CA1 region. Brain Res 863 (2000) 259-265
34. Matsuyama S., Matsumoto A., Enomoto T., and Nishizaki T. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus. Eur J Neurosci 12 (2000) 3741-3747
35. Itoh A., Akaike T., Sokabe M., Nitta A., Iida R., Olariu A., et al. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur J Pharmacol 382 (1999) 167-175
36. Chen L., Yamada K., Nabeshima T., and Sokabe M. alpha7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 50 (2006) 254-268
37. Levin E.D., Bettegowda C., Blosser J., and Gordon J. AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10 (1999) 675-680
38. Woodruff-Pak D.S., Green J.T., Coleman-Valencia C., and Pak J.T. A nicotinic cholinergic agonist (GTS-21) and eyebrink classical conditioning: Acquisition, retention, relearning in older rabbits. Exp Aging Rev 26 (2000) 323-336
39. Dziewczapolski G., Glogowski C.M., Masliah E., and Heinemann S.F. Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29 (2009) 8805-8815
40. Wang H.Y., Stucky A., Liu J.J., Shen C., Trocmé-Thibierge C., and Morain P. Dissociating β-amyloid from α7 nicotinic receptor by a novel therapeutic agent, S 24795 normalizes α7 nicotinic acetylcholine and NMDA receptor function in Alzheimer's disease brain. J Neurosci 29 (2009) 10961-10973
41. Bullock R., and Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract 59 (2006) 817-822
42. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I.f.t.M.S.g. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. JAMA 291 (2004) 317-324
43. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38 (1999) 735-767
44. Aracava Y., Pereira E.F., Maelicke A., and Albuquerque E.X. Memantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J Pharmacol Exp Ther 312 (2005) 1195-1205
45. Capsoni S., Giannotta S., and Cattaneo A. Nerve growth factor and galantamine ameliorate early sign of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99 (2002) 12432-12437
46. Takada Y., Yonezawa A., Kume T., Katsuki H., Kaneko S., Sugimoto H., et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther 306 (2003) 772-777
47. Arias E., Ales E., Gabilan N., Cano-Abad M., Villarroya M., Garcia A., et al. Galantamine prevents apoptosis induced by β-amyloid and thiapsigargin: Involvement of nicotinic acetylcholine receptors. Neuropharmacology 46 (2004) 103-114
48. Yamada K., Takayanagi M., Kamei H., Nagai T., Dohniwa M., Kobayashi K., et al. Effects of memantine and donepezil on amyloid β-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 162 (2005) 191-199